Emergence of a pandrug-resistant VIM-1-producing Providencia stuartii clonal strain causing an outbreak in a Greek intensive care unit

International Journal of Antimicrobial Agents
Evangelia DoukaChristina Routsi

Abstract

Here we describe an outbreak caused by a pandrug-resistant Providencia stuartii strain involving 15 critically ill patients in a Greek intensive care unit (ICU) during September-November 2011. All isolates harboured the blaVIM-1 gene and a class 1 integron structure of 1913 bp as well as blaSHV-5 and blaTEM-1. Pulsed-field gel electrophoresis (PFGE) demonstrated that isolates from all 15 patients belonged to a single P. stuartii clonal type. As all of the infected patients were hospitalised during overlapping time periods, horizontal intra-ICU transmission was considered as the main route for the dissemination of the outbreak strain. The outbreak ended following reinforcement of infection control measures, including implementation of additional barrier precautions for infected patients.

References

Jan 1, 1995·Antimicrobial Agents and Chemotherapy·C LévesqueP H Roy
Nov 8, 2003·Journal of Clinical Microbiology·N A SabbubaD J Stickler
Dec 23, 2003·The Journal of Antimicrobial Chemotherapy·Mario TumbarelloRoberto Cauda
Dec 3, 2010·Journal of Clinical Microbiology·Patrice NordmannTimothy R Walsh
Jul 29, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A-P MagiorakosD L Monnet
May 9, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Alexandre P ZavasckiAna C Gales
Mar 15, 2013·Journal of Clinical Microbiology·Shiraz Gefen-HaleviNathan Keller

❮ Previous
Next ❯

Citations

Dec 18, 2015·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Barbara AlbigerUNKNOWN European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group
Oct 19, 2017·Antimicrobial Agents and Chemotherapy·Karlijn van LoonMargreet C Vos
Sep 25, 2017·Applied and Environmental Microbiology·Hugo OliveiraJoana Azeredo
Oct 6, 2019·The Journal of Antimicrobial Chemotherapy·Stamatis KarakonstantisAchilleas Gikas
Oct 14, 2020·Current Microbiology·Amparo HoardMaria Soledad Ramirez
Jan 8, 2021·Infection and Drug Resistance·Maria RusLuminita Baditoiu
Jan 13, 2021·Infection and Immunity·Jordan R GastonChelsie E Armbruster

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.